A pharmaceutically acceptable salt of 3-(4-chloro-2-fluorobenzyl)-2-methyl-n-(5-methyl-1h-pyrazol-3-yl)-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine compound

Abstract

The present invention provides a pharmaceutically acceptable salt of 3-(4-chloro-2-fluorobenzy1)-2-methyl-N-(5-methyl-1H-pyrazol-3-y1)-8-(morpholinomethyDimidazo[1,2-b]pyridazin-6-amine compound useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.